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STAT6 (signal transducers and activators of transcription 6)-deficient (STAT6/) mice have defects in IL-4- and IL-13-
mediated functions and thus have a reduced TH2-mediated immune response. Conversely, they have elevated levels of IL-2
and thus an increased TH1-mediated immune response. To assess the relative impact of reduced TH2- and elevated
TH1-dependent immune responses on HSV-1 infection, vaccinated and mock-vaccinated STAT6
/ mice were challenged
ocularly with HSV-1. Mock-vaccinated STAT6/ mice were as susceptible to lethal HSV-1 infection as parental BALB/c mice.
Mock-vaccinated STAT6/ mice had reduced HSV-1 titers in their eyes compared to BALB/c mice. Furthermore, mock-
vaccinated STAT6/ mice had significantly less corneal scarring than their BALB/c counterparts. Vaccination induced
significantly higher serum-neutralizing antibody titers in STAT6/ mice compared to BALB/c mice, while completely
protecting both types of mice against HSV-1-induced death and corneal scarring. Vaccinated STAT6/ mice had reduced
HSV-1 titers in their eyes compared to BALB/c mice. Lymphocytes from both vaccinated and mock-vaccinated STAT6/ mice
secreted higher amounts of IL-2 than lymphocytes from BALB/c mice, in the presence or absence of stimulation with
UV-inactivated HSV-1. Finally, depletion of IL-2 increased ocular virus replication in STAT6/ mice to levels similar to that
measured in BALB/c mice. Our results suggest that in the absence of the STAT6 pathway, IL-2-mediated immune responsesce andINTRODUCTION
Following primary ocular herpes simplex virus (HSV)
infection, the virus establishes a latent infection in the
sensory neurons of the trigeminal ganglia (TG) (Cook
and Stevens, 1976; Rock et al., 1987). Ocular HSV-1 in-
fections are among the most frequent serious viral eye
infections in the United States and are a major cause of
viral-induced blindness (Barron et al., 1994; Dawson,
1984; Wilhelmus et al., 1996). Ocular infection with HSV-1
can cause eye disease ranging in severity from blepha-
ritis, conjunctivitis, and dendritic keratitis, to disciform
stromal edema and necrotizing stromal keratitis (Binder,
1984; Dawson, 1984; Dawson and Togni, 1976). From
time to time during the life of the latently infected indi-
vidual, the virus can reactivate, travel back to the eye,
and cause recurrent disease. HSV-1-induced corneal
scarring following reactivation from latency is a major
cause of corneal scarring (Barron et al., 1994; Dawson,
1984; Dawson and Togni, 1976).
Following ocular infection with wild-type HSV-1 strain
McKrae, increased immunopathology in the eyes is asso-
ciated with increased virus replication (Ghiasi et al., 1999c,
1998). Preventing or reducing virus replication in the eye
should be the most efficient method of preventing immu-© 2002 Elsevier Science (USA)
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286nopathology that leads to loss of vision. We have shown
previously that increased replication of HSV-1 in the eye
and HSV-1-induced eye disease both correlate with the
presence of IL-4 (Ghiasi et al., 1998). Detrimental effects on
host animals were also observed in experiments in which
IL-4-expressing transgenic mice were infected with respi-
ratory syncytial virus (Fischer et al., 1997) and when influ-
enza virus infection was treated in vivo with recombinant
IL-4 (Moran et al., 1996). Furthermore, IL-4 expression by a
recombinant vaccinia virus exacerbated infection (Cheers
et al., 1999). More recently it has been shown that, similar to
IL-4, IL-13 may also have a pleiotropic effect on virus clear-
ance and associated pathology (Wills-Karp et al., 1998; Zhu
et al., 1999).
Thus, both IL-4 and IL-13 may negatively effect virus
clearance. STAT6/ mice, which are deficient in both
IL-4 and IL-13 production (Takeda et al., 1996, 1997),
were used here to determine if in the absence of IL-4 and
IL-13 clearance of HSV-1 from the eye and protection
against HSV-1-induced eye disease would be affected.
We report here that compared to parental BALB/c mice or
BALB/c-derived IL-4 knockout mice (Ghiasi et al., 1999c),
the BALB/c-derived STAT6/ mice had less HSV-1-in-
duced corneal scarring and blepharitis, lower HSV-1 ti-
ters in their eyes, and higher levels of IL-2 production, in
the presence or absence of in vitro stimulation. In vivo
/are up-regulated. This, in turn, leads to faster viral clearan
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depletion of IL-2 in STAT6 mice produced increased
ocular HSV-1 titers. These results suggest that both IL-4
and IL-13 contribute to increased virus replication and
ocular pathology in HSV-1-infected mice, perhaps by
down-regulating IL-2.
RESULTS
HSV-1-neutralizing antibody
Two independent experiments were performed. In
each experiment, 5 STAT6/ and 5 parental BALB/c mice
were vaccinated three times with avirulent HSV-1 strain
KOS in MEM or mock-vaccinated with MEM alone, as
described under Materials and Methods. Three weeks
after the third vaccination, sera were collected and indi-
vidually heat-inactivated. Neutralization titers of these
sera were then determined by plaque-reduction assays.
Each experiment gave similar results, allowing the data
from both experiments to be combined to increase sta-
tistical power. The average neutralizing antibody titer for
vaccinated STAT6/ mice was significantly higher than
for vaccinated BALB/c mice (Table 1, P  0.04, Student’s
t test). As expected, both vaccinated groups had signif-
icantly higher neutralizing antibody titers than the mock-
vaccinated mice (P  0.0001, Student’s t test).
Ig subtypes
Sera from vaccinated mice were analyzed for the rel-
ative expression of each immunoglobulin isotype (Table
2). No significant differences were detected between the
two groups for IgG1, IgG2a, and IgG2b. In contrast,
STAT6/ mice had significantly lower IgG3, IgA, and IgM
than parental BALB/c mice (P  0.005, P  0.0001,
and P  0.005, respectively).
Vaccine protection against lethal ocular challenge
Vaccinated and mock-vaccinated STAT6/ and
BALB/c mice were challenged ocularly with 2  105
PFU/eye of HSV-1 strain McKrae, as described under
Materials and Methods. All of the vaccinated STAT6/
and BALB/c mice survived lethal ocular challenge (Table
3, left panel). The vaccine-induced protection was highly
significant for both groups (P  0.0001) compared to
their mock-vaccinated counterparts. Thus, even in the
absence of STAT6, vaccination protected 100% of the
mice against lethal ocular challenge.
Protection against blepharitis
Herpetic blepharitis was measured 7 days after ocular
challenge as described under Materials and Methods. Vac-
cinated STAT6/ and BALB/c mice were completely pro-
tected against blepharitis (Table 3, middle panel). In con-
trast, mock-vaccinated BALB/c mice exhibited more bleph-
aritis than the mock-vaccinated STAT6/ (P  0.04).
Protection against corneal scarring
Corneal scarring was measured 28 days after ocular
challenge, as described under Materials and Methods.
All of the vaccinated mice, STAT6/ and BALB/c, were
completely protected against corneal scarring (Table 3,
right panel). This protection was highly significant when
compared with mock-vaccinated BALB/c mice (P 
0.0001, Student’s t test). Unlike BALB/c mice, mock-
vaccinated STAT6/ mice had no corneal scarring. Thus,
corneal scarring was greatly reduced in STAT6/ mice.
HSV-1 ocular clearance in STAT6/ mice
Tear films from mice infected ocularly with 2  105
PFU/eye of HSV-1 (strain McKrae) were collected from 10
eyes/group at various times postinfection and the
amount of infectious HSV-1 was determined (Figs. 1A
and 1B). Both mock-vaccinated (Fig. 1A) and vaccinated
(Fig. 1B) STAT6/ mice had lower ocular HSV-1 titers
during Days 1–7 postchallenge than their corresponding
BALB/c mice (P  0.05). In vaccinated STAT6/ mice,
virus was completely cleared by Day 2 (Fig. 1B). In
TABLE 2
Immunoglobulin Subtypes in the Blood of Vaccinated STAT6/
and BALB/c Micea
Ig subtype
STAT6/ BALB/c
PbVaccinated Mock-vaccinated Vaccinated
IgG1 2.4 0.10 1.9 0.12 2.4 0.02 P 0.7
IgG2a 2.6 0.07 1.5 0.03 2.6 0.09 P 0.9
IgG2b 1.9 0.17 1.8 0.08 2.3 0.07 P 0.08
IgG3 1.0 0.06 0.9 0.14 1.5 0.10 P 0.005
IgA 1.6 0.12 1.1 0.40 2.3 0.05 P 0.0001
IgM 0.9 0.09 0.8 0.07 1.5 0.11 P 0.005
a Optical density (OD) of immunoglobulin subtypes was determined
(as described under Materials and Methods) in sera collected from five
vaccinated or mock-vaccinated STAT6/ mice and 5 vaccinated
BALB/c mice 3 weeks after the third vaccination.
b Student’s t test comparing results from vaccinated STAT6/ mice to
vaccinated BALB/c mice.
TABLE 1
Neutralizing Antibody Titers in Vaccinated
and Mock-Vaccinated Micea
Vaccine
Neutralizing antibody titer
STAT6/ BALB/c
KOS 2019 232 989 195
Mock 33 15 41 21
P (KOS vs mock)b 0.0001 0.0001
P (vs vaccinated STAT6/)b 0.002
a Ten mice per group (from two separate experiments) were vacci-
nated or mock-vaccinated three times and bled 3 weeks after the third
vaccination as described under Materials and Methods. Neutralization
titers on all 10 sera combined from two separate experiments are
expressed as the reciprocal of the geometric means  SEM.
b Student’s t test.
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contrast, in vaccinated BALB/c mice, HSV-1 was not
completely cleared until Day 6 (Fig. 1B). Mock-vacci-
nated STAT6/ mice also cleared virus from their eyes
faster than mock-vaccinated BALB/c mice (Fig. 1A). Thus,
in both mock-vaccinated and vaccinated mice, the ab-
sence of STAT6 appeared to enhance HSV-1 clearance.
To determine if vaccinated STAT6/ would be protected
against higher doses of challenge virus, additional mice
were vaccinated or mock-vaccinated as above and vacci-
nated mice were challenged ocularly with 2 106 PFU/eye.
Tear films from infected mice (10 eyes/group) were col-
lected (Fig. 1C). As above, vaccinated STAT6/ mice had
significantly lower virus titers in their eyes than BALB/c
mice (Fig. 1C). Thus, regardless of vaccination status or
challenge dose, the absence of STAT6 appeared to in-
crease clearance of HSV-1 from the eye.
CTL assay
Since the presence of a strong TH1 response corre-
lates with high CTL activity, we examined CTL responses
in STAT6/ mice. STAT6/ mice and BALB/c mice were
immunized as above. Figure 2 shows that immunized
STAT6/ mice had slightly higher but not significant
HSV-specific cytotoxicity than immunized BALB/c mice
(P  0.1). Mock-immunized mice from either group did
not have any significant CTL response (Fig. 2).
In vitro cytokine secretion by STAT6/ mice
Three weeks after the third vaccination or mock vacci-
nation, we stimulated cultured splenocytes isolated from
BALB/c and STAT6/mice with UV-inactivated HSV-1 strain
McKrae. Subsequently the levels of IL-2, IL-4, and IFN-
secreted into the media were analyzed by ELISA (as de-
scribed underMaterials andMethods). As shown in Fig. 3A,
splenocytes from STAT6/ mice, regardless of vaccination
or stimulation, secreted high levels of IL-2. In contrast, only
splenocytes from vaccinated BALB/c mice secreted IL-2
after in vitro stimulation. These differences were highly
significant (P  0.001).
Splenocytes from vaccinated STAT6/ mice also se-
creted high levels of IFN- with or without stimulation
(Fig. 3B). In contrast to IL-2 secretion patterns, lympho-
cytes from mock-vaccinated STAT6/ mice did not se-
crete any IFN-, either with or without stimulation (Fig.
3B). Similar to STAT6/ mice, lymphocytes from vacci-
nated BALB/c mice produced IFN- after in vitro stimu-
lation (Fig. 3B). However, unstimulated BALB/c lympho-
cytes did not produce IFN-.
As expected, cultured spleen cells from vaccinated
BALB/c mice secreted IL-4 in response to stimulation,
whereas cells from STAT6/ mice (which are deficient in
IL-4) did not secrete any IL-4 (Fig. 3C). These results sug-
gest that both mock-vaccinated and vaccinated STAT6/
mice continuously secrete IL-2 with or without in vitro stim-
ulation. Since we and others previously showed a correla-
tion between high levels of IL-2 or IFN- and reduced virus
replication (Cantin et al., 1995; Ghiasi et al., 1998; Smith et
al., 1994; Yu, Manickan, and Rouse, 1996), the above find-
ings suggest that faster virus clearance from the eyes of
STAT6-deficient mice may be due to elevated and/or con-
tinuously high IL-2 in these mice.
Depletion of IL-2 by antibody
The above results suggested that the reduction in
virus titers in the tears of STAT6/ mice might be due to
the presence of high levels of IL-2. To test this hypothe-
sis, STAT6/ mice were injected with 500 g of IL-2
mAb. Injections were given on Days3,2,1,1,2,
and 3 relative to HSV-1 ocular challenge. Tear films
from the challenged mice were collected from 10 eyes/
group and infectious virus titers were determined. In
STAT6/ mice, depletion of IL-2 by mAb increased ocu-
lar HSV-1 titers to levels at least comparable to that seen
in BALB/c mice (Fig. 4). These results strongly support
TABLE 3
Survival and Eye Disease Following Lethal Ocular Challenge of Vaccinated and Mock-Vaccinated Micea
Survival/totalb Blepharitisc Corneal scarringc
Vaccined STAT6/ BALB/c STAT6/ BALB/c STAT6/ BALB/c
KOS 20/20 20/20 0 0 0 0
(100%) (100%)
Mock 4/20
(20%)
5/20
(25%)
1.9 0.2 2.8 0.4 0 1.1 0.2
P (KOS vs mock) 0.0001 0.0001 0.0001 0.0001 1.0 0.0001
P (vs mock- vaccinated
STAT6/)
0.04
a Mice were vaccinated three times and challenged ocularly with McKrae as described under Materials and Methods. Blepharitis was measured
7 days after ocular challenge. Survival and corneal scarring were measured 28 days after ocular challenge.
b Fisher’s exact test.
c Student’s t test.
d Survival and eye disease data are based on results combined from two independent experiments with similar results (10 mice per group/
experiment).
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the hypothesis that the decreased virus titers in STAT6/
mice were due to the continuous production of IL-2.
DISCUSSION
Viral replication occurs in the eye after primary ocular
HSV-1 infection. Eye diseases can result from direct
damage inflicted on the corneal tissue by HSV-1 or indi-
rectly from cytokines and chemokines released by cells
infiltrating the cornea following infection (Easty et al.,
1987; Ghiasi et al., 1999c, 1998, 1995b). The virus is
usually completely cleared from the eye between 7 and
10 days after ocular infection (Ghiasi et al., 1995a, 2000,
1999b, 1998, 1995b). Longer virus clearance times lead to
increased eye disease (Ghiasi et al., 1995a). In order to
identify cellular phenotypes of the immune system and
cytokines that can reduce the duration of, or eliminate,
virus replication in the eyes, we have compared the
length of time for complete virus clearance in knockout
mice lacking the genes for IL-2, IL-4, IFN-, IL-12a, IL-
12b, PFP, NOS2, NOS3, STAT4, CD4, CD8, 2m, or AO
(Ghiasi et al., 1999a, 2000, 1999b, 1999d, 1997; and un-
published results). We have found that IL-4-deficient
mice cleared virus in 5–7 days, whereas other knockout
mice and the parental wild-type strain took 7–10 days for
virus clearance after ocular infection. In the present
study, we compared STAT6/ mice with age- and sex-
matched parental BALB/c mice to determine the effect
that elevated TH1 (IL-2, IFN-) and the absence of TH2
immune responses (IL-4, IL-13) have on protection
against HSV-1 infection.
The results presented here suggest that STAT6 re-
sponses were not essential for vaccine-induced neutral-
izing antibody titers or for vaccine-induced protection
against lethal HSV-1 challenge. That is, following vacci-
nation, HSV-1-neutralizing antibody titers of STAT6/
mice were significantly higher than those induced in
BALB/c mice. However, we have also shown that
STAT6/ mice had significantly lower concentrations of
certain immunoglobulin subtypes than BALB/c mice, in-
cluding IgG3, IgA, and IgM. Generally, vaccination
against viruses induces strong IgG2a and IgG2b re-
sponses that contribute to neutralizing antibody titers
(Nguyen et al., 1994). TH2 cells are involved in antibody-
mediated immunity (Charlton and Lafferty, 1995). Surpris-
ingly, even though these cells are absent, vaccinated
STAT6/ mice had increased rather than decreased
FIG. 1. Virus titers in mouse eyes following ocular challenge. Three
weeks after the third vaccination, STAT6/ (open symbols) and BALB/c
mice (closed symbols) were challenged ocularly and the presence of
HSV-1 in tear films was monitored daily as described under Materials
and Methods. For each point, the virus titer (Y-axis) represents the
average of the titers from 10 eyes. The error bars indicate the standard
errors. (A) Mock-vaccinated mice infected with 2  105 PFU/eye; (B)
KOS vaccinated mice infected with 2  105 PFU/eye; and (C) KOS
vaccinated mice infected with 2  106 PFU/eye.
FIG. 2. CTL activity in vaccinated STAT6/ mice. Splenocytes from 3
vaccinated and 3 mock-vaccinated mice per group were prepared as
described under Materials and Methods. CD4 T cells were removed
by incubating the splenocytes with L3T4 mAb for 30 min. LDH-release
assays were done in triplicate with splenocytes as effector cells and
HSV-1-infected CL7 cells as target cells (as described under Materials
and Methods). Each point represents mean SEM from three separate
experiments.
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neutralizing antibody titers compared to parental BALB/c
mice. This is in agreement with previously published
reports showing that IL-2 increases T-cell responses
(Kasaian and Biron, 1990; Kast et al., 1990; Weinberg and
Merigan, 1988) and neutralizing antibody titers (Lee et al.,
1999; Reddy et al., 1989). It is possible that the lack of a
TH2 response in STAT6
/ mice contributes to lower
concentrations of IgG3, IgA, and IgM. The lower IgA and
IgM concentrations in STAT6/ mice may, in turn, lead to
up-regulation of neutralizing antibody titers in vaccinated
STAT6/ mice, as compared to vaccinated BALB/c mice.
Alternatively, since STAT6/ mice have defects in immu-
noglobulin class switching to IgE (Grusby, 1997; Kaplan
et al., 1998; Stamm et al., 1998; Takeda et al., 1997), this
may prevent masking of IgG by IgE antibodies (Lehrer,
1977), thereby causing an increasing neutralizing anti-
body titer. Previously, we have shown that, after vaccina-
tion, IL-4/ mice have HSV-1-neutralizing antibody titers
comparable to those induced in the parental BALB/c
mice (Ghiasi et al., 1999b). This difference between IL-
4/ and STAT6/ mice is probably due to the fact that
IL-4-deficient mice have specific defects in IL-4-medi-
ated functions (Kopf et al., 1993), whereas STAT6-defi-
cient mice have defects in both IL-4- and IL-13-mediated
functions (Kaplan et al., 1998; Stamm et al., 1998; Urban
et al., 1998).
Both vaccinated and mock-vaccinated STAT6/ mice
had reduced virus titers in their eyes. Mock-vaccinated
STAT6/ mice were able to clear virus faster than
BALB/c mice. This decrease in viral titers is probably due
to an increase in the IL-2 response in STAT6/ mice.
Splenocytes from both vaccinated and mock-vaccinated
STAT6/ mice secreted IL-2 in vitro with or without
stimulation. However, only splenocytes from vaccinated
STAT6/ mice secreted IFN-. IFN- has been shown to
increase the rate of virus clearance from the site of
FIG. 4. Effect of IL-2 depletion on virus titers in mouse eyes. STAT6/
mice were depleted of IL-2 with anti-IL-2 mAb and infected ocularly
with 2 105 pfu of McKrae per eye. The presence of HSV-1 in tear films
was monitored daily as described under Materials and Methods. Each
point represents the average virus titer (Y-axis) from 10 eyes. The error
bars indicate the standard errors.
FIG. 3. In vitro cytokine secretion by splenocytes from STAT6/
mice. STAT6/ and BALB/c mice were vaccinated or mock-
vaccinated, as described under Materials and Methods. Spleens
from three mice per group were harvested. Single cell suspensions
of splenocytes were prepared and subjected to in vitro stimulation
for 72 h with 10 PFU/cell of UV-inactivated McKrae. The superna-
tants were then tested in triplicate for IL-2, IL-4, and IFN- secretion
by ELISA (as described under Materials and Methods). Each point
represents the mean  SEM of the titers from three separate
experiments.
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infection (Karupiah et al., 1993; Tishon et al., 1995). How-
ever, the absence of IFN- secretion by splenocytes from
mock-vaccinated mice makes it unlikely that IFN- is
directly involved in faster virus clearance in STAT6/
mice.
IgA is the predominant isotype in mucosal secretion
and serves as the first line of humoral defense at the
mucosal surface (McLean et al., 1996; Renegar and
Small, 1991). However, it is unlikely that IgA played an
important role in the more rapid clearance of HSV-1 from
the eyes of STAT6/ mice compared to wild-type BALB/c
mice. Although vaccinated STAT6/ mice had increased
clearance of HSV-1 from their eyes and increased IgA
levels compared to unvaccinated STAT6/ mice, even
the unvaccinated wild-type (BALB/c) mice had more IgA
than the vaccinated STAT6/ mice. Faster virus clear-
ance in STAT6/ mice is more likely associated with the
absence of IL-4 and IL-13. IL-4 is a pleiotropic cytokine
involved in development of TH2 responses and conse-
quently induction of humoral immunity (Nelms et al.,
1999), in the differentiation and maturation of B cells, and
in the switch from IgE to IgG. IL-4 may also be involved
in switching to IgA (Stavnezer, 1996). Previously we found
more rapid clearance of HSV-1 from eyes of IL-4-defi-
cient mice compared to wild-type BALB/c mice (Ghiasi et
al., 1999b). The clearance of HSV-1 from the eyes of
STAT6-deficient mice, which lacks both IL-4 and its re-
lated cytokine IL-13, was even more rapid, suggesting
that eliminating IL-13 further enhanced viral clearance.
In this study we show by IL-2 depletion studies that
IL-2 plays a major role in virus clearance from the eyes
of both vaccinated and mock-vaccinated STAT6/ mice.
We found that depletion of IL-2 in STAT6/ mice in-
creased viral replication in nonimmunized STAT6/
mice. Thus, this study suggests that the correlation we
previously reported between IL-2 in the corneal tissues
and reduced virus replication in the eye (Ghiasi et al.,
1998, 1995b) is a functional relationship.
Mock-vaccinated STAT6/ mice had less corneal
scarring than mock-vaccinated BALB/c mice. This de-
creased corneal scarring is in contrast with a previous
report showing that treatment of mice with anti-IL-2 sig-
nificantly reduces the incidence and severity of corneal
inflammation (Hendricks et al., 1992). A possible expla-
nation for the reduced corneal scarring in STAT6/ mice
may be faster clearance of the virus from the eye as well
as lower virus titers.
In summary, the faster clearance of virus and the
decreased eye disease seen in STAT6/ mice appears
to be due to the increased and/or continuously high IL-2
levels seen in these mice. Faster virus clearance also
occurs in IL-4/ mice (Ghiasi et al., 1999b), again pre-
sumably because they have elevated IL-2 responses.
However, virus clearance appeared to be more rapid in
the STAT6/ than in the IL-4/ mice (Ghiasi et al.,
1999b). In addition, the STAT6/ mice had decreased
eye disease, while the IL-4/ mice did not (Ghiasi et al.,
1999b). This suggests that the lack of IL-13 (along with
the lack of IL-4) in the STAT6/ mice contributes to the
phenotype differences between IL-4/ mice and
STAT6/ mice, presumably by further increasing the IL-2
levels above that of IL-4/ mice.
MATERIALS AND METHODS
Virus and cells
Plaque-purified HSV-1 strains were grown in rabbit
skin (RS) cell monolayers in minimal essential medium
(MEM) containing 5% fetal calf serum. McKrae, a stromal
disease causing neurovirulent HSV-1 strain, was used as
the ocular challenge virus. KOS, a nonneuroinvasive non-
stromal disease-producing strain, was used as a live
virus vaccine.
Mice
Inbred female BALB/c mice and homozygous female
BALB/c-STAT6/ mice (The Jackson laboratory, Bar Har-
bor, ME) were used. All mice used were between 5 to 8
weeks old.
Vaccinations
Mice were vaccinated ip three times at 3-week inter-
vals with 2 105 PFU of live KOS in tissue culture media.
Mock-vaccinated mice were similarly injected, but with
tissue culture medium (MEM) alone or tissue culture
medium collected from mock-infected RS cells.
Depletion of IL-2
Each mouse received iv injections of 500 g purified
IL-2 monoclonal antibody (S4B6 mAb, NCCC, Minneap-
olis, MN) in 100 l of PBS on Days 3, 2, 1, 1, 2,
and3 relative to HSV-1 ocular challenge. The efficiency
of IL-2 depletion was monitored by FACS analysis.
Cytotoxic T-lymphocyte (CTL) assay
STAT6/ and BALB/c mice were immunized by ip
injection as above. Three weeks after the third vaccina-
tion, three mice per group were sacrificed and spleens
were removed from immunized and mock-vaccinated
mice. Single-cell suspensions were prepared from the
spleens as described (Ghiasi et al., 1994). CD4 T cells
were removed twice by pretreating spleen cells with GK
1.5 antibody and low tox M rabbit complement (Cedar-
lane) for 30 min at 4°C. For each 1  107 spleen cells,
100 g of GK 1.5 antibody and a 1:10 dilution of rabbit
complement were used. The viable cells were collected,
washed three times, counted, and used without in vitro
restimulation to measure HSV-1 class I-restricted CTL
activity. The CL7 target cells were infected with 10 PFU/
cell of HSV-1 strain McKrae for 4 h and washed three
times with assay medium. The CTL activity was mea-
sured using the lactate dehydrogenase (LDH) release
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assay in 96-well round-bottom plates. Target cells (2 
104 cells/well) in a 100-l volume were incubated with
100 l of effector cells at various effector-target ratios for
4 h in phenol red-free RPMI 1640 containing 3% fetal calf
serum. Fifty microliters of supernatant per well was then
transferred to 96-well plates, and lysis was determined
by measuring LDH release using the Cytotox 96 assay kit
(Promega Corp., Madison, WI). The percentage of CTL
was calculated by the following formula: specific lysis 
{optical density (OD) of experimental LDH release  OD
of effector cell spontaneous LDH release  OD of target
cell spontaneous LDH release}/{maximum target cell
LDH release  OD of target cell spontaneous LDH
release}  100%. All determinations were performed in
triplicate.
In vitro cytokine assay
Lymphocytes isolated in parallel with the CTL assay
were resuspended at 1  106 cells/ml in RPMI 1640
supplemented with 10% heat-inactivated fetal bovine se-
rum and 5  105 mM 2-mercaptoethanol (2-ME). Cells
were cultured in triplicate in the presence or absence of
10 PFU/cell of UV-inactivated HSV-1 strain McKrae for 3
days at 37°C in 5% CO2. Culture supernatants were
collected 3 days after incubation and the concentrations
of interleukin-2 (IL-2), interleukin-4 (IL-4), and gamma
interferon (IFN-) were determined by enzyme-linked
immunosorbent assay (ELISA) (Becton Dickinson, San
Diego, CA).
Serum-neutralizing antibody titers
Antibody titers were determined in sera collected 3
weeks after the final vaccination by 50% plaque-reduc-
tion assays (as described previously, Ghiasi et al., 1994).
Analysis of immunoglobulins in the sera
IgG1, IgG2a, IgG2b, IgG3, IgM, and IgA concentrations
were determined in sera collected from vaccinated and
mock-vaccinated mice using a mouse immunoglobulin
isotyping ELISA kit and following the protocol described
by the manufacturer (Becton Dickinson, San Diego, CA).
Ocular challenge
Mice were challenged ocularly without corneal scari-
fication with 2  105 or 2  106 PFU of HSV-1 strain
McKrae per eye, in 1 l of tissue culture media as
described previously (Ghiasi et al., 1994).
Titration of virus in tears
Tear films were collected from both eyes of 5 mice per
group at various times as described (Ghiasi et al., 1995a).
Each swab was placed in 0.5 ml tissue culture medium
and squeezed, and the amount of virus was determined
by a standard plaque assay on RS cells.
Monitoring eye disease
The severity of blepharitis and corneal scarring in
surviving mice was scored in a masked fashion using a
0 to 4 scale as described (Ghiasi et al., 1995a).
Statistical analysis
Protective parameters were analyzed by the Student’s
t test and Fisher’s exact test using Instat (GraphPad, San
Diego, CA). Results were considered to be statistically
significant when the P value was  0.05.
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